MedTrace Logo

Single-cell Sequencing Analysis of Resectable/Borderline Resectable Pancreatic Cancer Patients

NCT06310902 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2024-03-15

No results posted yet for this study

Summary

Preoperative neoadjuvant chemotherapy is widely used in treating patients with borderline resectable pancreatic cancer (BRPC). However, there are limitations in this field. Treatment strategies and definitions for BRPC patients differ, and the efficacy and prognosis of neoadjuvant chemotherapy vary greatly.This study aims to utilize single-cell sequencing technology to investigate in-depth the composition and interactions of the tumor microenvironment in patients from the surgical-only group and the preoperative neoadjuvant chemotherapy group.

Conditions

  • Pancreatic Neoplasms

Interventions

DIAGNOSTIC_TEST

Single-cell Sequencing Analysis

Identification of rare cell populations, the characterization of cell types and subtypes, and the discovery of novel cell states.

Sponsors & Collaborators

  • Fujian Medical University Union Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-01
Primary Completion
2026-03-01
Completion
2026-09-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06310902 on ClinicalTrials.gov